Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zeprumetostat + glofitamab + GemOx in relapsed/refractory DLBCL
ChiCTR2600126314Phase 4Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of zeprumetostat in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by Jiangsu Provincial People's Hospital. Primary endpoints: Complete response rate (CRR) and Incidence of treatment-related adverse events and serious adverse events. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
zeprumetostat
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2600126314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126314.